Ines G. Muñoz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ines G. Muñoz has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Javier Blanco
Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain
10 shared publications - Guillermo Montoya
Structural Biology and Biocomputing Programme, Spanish National Cancer Centre (CNIO) Macromolecular Crystallography Group, c/Melchor Fdez Almagro 3, 28029 Madrid, Spain
9 shared publications Guillermo Montoya
6 shared publications- Pilar Redondo
Macromolecular Crystallography Group, Structural Biology and Biocomputing Programme, Spanish National Cancer Research Centre (CNIO), c/Melchor Fernandez Almagro 3, 28029 Madrid, Spain
5 shared publications - Jerry Ståhlberg
Department of Molecular Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden
4 shared publications - Alicia Palacios
Universidad Internacional de La Rioja (España)
3 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
The oncogenic CCDC6-RET fusion protein is a dual ATP- and ADP-dependent kinase
Gene fusion products involving protein kinases are known drivers in human cancers and actionable targets for personalized therapy, yet the structural and molecular determinants that control their function are largely unexplored. Here we show that a CCDC6-RET fusion protein, a driver and therapeutic target in lung and thyroid cancers, is a highly active dimeric kinase. Time-resolved mass spectrometry together with a robust biochemical and biophysical characterization reveal that CCDC6-RET functions as a dual ATP- and ADP-dependent kinase able to bind both nucleotides and to use them as phosphoryl donors. We also identify a crosstalk between the C-terminal and the activation segments controlling both the processing and the catalytic activity of the fusion protein. Furthermore, a 3D-structural assembly of a CCDC6-RET homodimer was generated combining single particle electron microscopy, small-angle X-ray scattering and in silico molecular dynamics simulations. Our structural model together with cross-linking mass spectrometry data demonstrated that CCDC6-RET in the inactive state forms a face-to-face dimer characterized by intermolecular-crosslinked activation segments. Upon nucleotide binding the catalytic domains swing apart and fast activation loop phosphorylation could be driven by a mechanism in cis. Our work uncovers the molecular and structural determinants that control the mechanism of CCDC6-RET autoactivation.
- 6 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessThe oncogenic CCDC6-RET fusion protein is a dual ATP- and ADP-dependent kinase
Gene fusion products involving protein kinases are known drivers in human cancers and actionable targets for personalized therapy, yet the structural and molecular determinants that control their function are largely unexplored. Here we show that a CCDC6-RET fusion protein, a driver and therapeutic target in lung and thyroid cancers, is a highly active dimeric kinase. Time-resolved mass spectrometry together with a robust biochemical and biophysical characterization reveal that CCDC6-RET functions as a dual ATP- and ADP-dependent kinase able to bind both nucleotides and to use them as phosphoryl donors. We also identify a crosstalk between the C-terminal and the activation segments controlling both the processing and the catalytic activity of the fusion protein. Furthermore, a 3D-structural assembly of a CCDC6-RET homodimer was generated combining single particle electron microscopy, small-angle X-ray scattering and in silico molecular dynamics simulations. Our structural model together with cross-linking mass spectrometry data demonstrated that CCDC6-RET in the inactive state forms a face-to-face dimer characterized by intermolecular-crosslinked activation segments. Upon nucleotide binding the catalytic domains swing apart and fast activation loop phosphorylation could be driven by a mechanism in cis. Our work uncovers the molecular and structural determinants that control the mechanism of CCDC6-RET autoactivation.
- Open Access
- 3 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Nanobodies as tools for studying human frataxin biology
Iron-sulfur clusters are essential cofactors for the accurate cellular function of many proteins. In eukaryotic cells, the biogenesis of most iron-sulfur clusters occurs in the mitochondria and involves the action of the Cys desulfurase supercomplex, which is activated by the protein frataxin (FXN). The decrease of FXN expression and/or function results in Friedreich’s ataxia (FRDA). In this work, several nanobodies specific to human FXN were selected via phage display, demonstrating a wide range of effects on Cys desulfurase activity and a strong interaction with FXN. Nanobody interaction stabilized wild-type and FRDA-related FXN variants in vitro. FXN-nanobody complexes were characterized by NMR, SAXS, and X-ray crystallography. Additionally, Nanobody expression was studied in human cells. The subcellular localization, direct interaction with FXN by in situ proximity ligation assay, effect on cell viability, Fe-S-dependent enzymatic activities, and oxygen consumption rates were analyzed. Significantly, nanobody expression did not alter these key metabolic variables, suggesting that the interaction with FXN did not disrupt the pathway. As a whole, our results suggest that nanobodies can serve as binding partners for mitochondrial FXN. However, the specific effect of the nanobodies on the conformational stability of FRDA-related FXN variants in cells should be investigated.
- 3 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessNanobodies as tools for studying human frataxin biology
Iron-sulfur clusters are essential cofactors for the accurate cellular function of many proteins. In eukaryotic cells, the biogenesis of most iron-sulfur clusters occurs in the mitochondria and involves the action of the Cys desulfurase supercomplex, which is activated by the protein frataxin (FXN). The decrease of FXN expression and/or function results in Friedreich’s ataxia (FRDA). In this work, several nanobodies specific to human FXN were selected via phage display, demonstrating a wide range of effects on Cys desulfurase activity and a strong interaction with FXN. Nanobody interaction stabilized wild-type and FRDA-related FXN variants in vitro. FXN-nanobody complexes were characterized by NMR, SAXS, and X-ray crystallography. Additionally, Nanobody expression was studied in human cells. The subcellular localization, direct interaction with FXN by in situ proximity ligation assay, effect on cell viability, Fe-S-dependent enzymatic activities, and oxygen consumption rates were analyzed. Significantly, nanobody expression did not alter these key metabolic variables, suggesting that the interaction with FXN did not disrupt the pathway. As a whole, our results suggest that nanobodies can serve as binding partners for mitochondrial FXN. However, the specific effect of the nanobodies on the conformational stability of FRDA-related FXN variants in cells should be investigated.
- Open Access
- 12 March 2025
- Published by Springer Nature in Research Square
Nanobodies as Novel Tools to Modulate Human Frataxin Stability and Function
Iron-sulfur clusters are essential cofactors for hundreds of proteins. In eukaryotic cells, the biogenesis of most iron-sulfur clusters occurs in the mitochondria and involves the Cys desulfurase supercomplex, which is activated by frataxin (FXN). The decrease of FXN expression, stability, and/or function results in Friedreich's ataxia (FA), a rare disease affecting 1 in 50,000 people. In this work, we propose modulating the conformational stability of FXN through nanobody interactions as a viable strategy to maintain FXN function. Several nanobodies specific to human FXN were selected via phage display, demonstrating a wide range of effects on Cys desulfurase activity. We focused on four nanobodies that exhibited strong interactions with FXN ( K D = 1–30 nM) and stabilized the pathogenic FXN variant G130V by increasing its Tm by 15°C. The interaction between nanobodies and FXN was characterized using various biophysical tools, including NMR, SAXS, and X-ray diffraction. Three of the nanobodies bind to a similar region, and the structures of the corresponding nanobody-FXN complexes were solved by X-ray diffraction, showing a similar binding mode. In contrast, the fourth nanobody binds to alpha-helix 1, as determined by NMR and SAXS. The biological effects of nanobody expression were studied in human cells. The subcellular localization, effect on cell viability, Fe-S-dependent enzymatic activities, and oxygen consumption rates were analyzed. The expression of nanobodies sharing the same binding mode did not alter these key metabolic variables, suggesting that the interaction with FXN did not disrupt the pathway. Overall, these results suggest that nanobodies can be employed as tutor mitochondrial proteins to investigate the function modulation of unstable pathogenic FXN variants in FA models.
- 12 March 2025
- Published by Springer Nature in Research Square
Open AccessNanobodies as Novel Tools to Modulate Human Frataxin Stability and Function
Iron-sulfur clusters are essential cofactors for hundreds of proteins. In eukaryotic cells, the biogenesis of most iron-sulfur clusters occurs in the mitochondria and involves the Cys desulfurase supercomplex, which is activated by frataxin (FXN). The decrease of FXN expression, stability, and/or function results in Friedreich's ataxia (FA), a rare disease affecting 1 in 50,000 people. In this work, we propose modulating the conformational stability of FXN through nanobody interactions as a viable strategy to maintain FXN function. Several nanobodies specific to human FXN were selected via phage display, demonstrating a wide range of effects on Cys desulfurase activity. We focused on four nanobodies that exhibited strong interactions with FXN ( K D = 1–30 nM) and stabilized the pathogenic FXN variant G130V by increasing its Tm by 15°C. The interaction between nanobodies and FXN was characterized using various biophysical tools, including NMR, SAXS, and X-ray diffraction. Three of the nanobodies bind to a similar region, and the structures of the corresponding nanobody-FXN complexes were solved by X-ray diffraction, showing a similar binding mode. In contrast, the fourth nanobody binds to alpha-helix 1, as determined by NMR and SAXS. The biological effects of nanobody expression were studied in human cells. The subcellular localization, effect on cell viability, Fe-S-dependent enzymatic activities, and oxygen consumption rates were analyzed. The expression of nanobodies sharing the same binding mode did not alter these key metabolic variables, suggesting that the interaction with FXN did not disrupt the pathway. Overall, these results suggest that nanobodies can be employed as tutor mitochondrial proteins to investigate the function modulation of unstable pathogenic FXN variants in FA models.
- Open Access
- 20 October 2023
- Published by Wiley in Advanced Science
- Vol. 10 (34) , e2304818
Dendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2
Administration of neutralizing antibodies (nAbs) has proved to be effective by providing immediate protection against SARS‐CoV‐2. However, dual strategies combining virus neutralization and immune response stimulation to enhance specific cytotoxic T cell responses, such as dendritic cell (DC) cross‐priming, represent a promising field but have not yet been explored. Here, a broadly nAb, TNT, are first generated by grafting an anti‐RBD biparatopic tandem nanobody onto a trimerbody scaffold. Cryo‐EM data show that the TNT structure allows simultaneous binding to all six RBD epitopes, demonstrating a high‐avidity neutralizing interaction. Then, by C‐terminal fusion of an anti‐DNGR‐1 scFv to TNT, the bispecific trimerbody TNTDNGR‐1 is generated to target neutralized virions to type 1 conventional DCs (cDC1s) and promote T cell cross‐priming. Therapeutic administration of TNTDNGR‐1, but not TNT, protects K18‐hACE2 mice from a lethal SARS‐CoV‐2 infection, boosting virus‐specific humoral responses and CD8+ T cell responses. These results further strengthen the central role of interactions with immune cells in the virus‐neutralizing antibody activity and demonstrate the therapeutic potential of the Fc‐free strategy that can be used advantageously to provide both immediate and long‐term protection against SARS‐CoV‐2 and other viral infections.
- 20 October 2023
- Published by Wiley in Advanced Science
- Vol. 10 (34) , e2304818
Open AccessDendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2
Administration of neutralizing antibodies (nAbs) has proved to be effective by providing immediate protection against SARS‐CoV‐2. However, dual strategies combining virus neutralization and immune response stimulation to enhance specific cytotoxic T cell responses, such as dendritic cell (DC) cross‐priming, represent a promising field but have not yet been explored. Here, a broadly nAb, TNT, are first generated by grafting an anti‐RBD biparatopic tandem nanobody onto a trimerbody scaffold. Cryo‐EM data show that the TNT structure allows simultaneous binding to all six RBD epitopes, demonstrating a high‐avidity neutralizing interaction. Then, by C‐terminal fusion of an anti‐DNGR‐1 scFv to TNT, the bispecific trimerbody TNTDNGR‐1 is generated to target neutralized virions to type 1 conventional DCs (cDC1s) and promote T cell cross‐priming. Therapeutic administration of TNTDNGR‐1, but not TNT, protects K18‐hACE2 mice from a lethal SARS‐CoV‐2 infection, boosting virus‐specific humoral responses and CD8+ T cell responses. These results further strengthen the central role of interactions with immune cells in the virus‐neutralizing antibody activity and demonstrate the therapeutic potential of the Fc‐free strategy that can be used advantageously to provide both immediate and long‐term protection against SARS‐CoV‐2 and other viral infections.
- Open Access
- 17 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-21
An allosteric switch between the activation loop and a c-terminal palindromic phospho-motif controls c-Src function
Autophosphorylation controls the transition between discrete functional and conformational states in protein kinases, yet the structural and molecular determinants underlying this fundamental process remain unclear. Here we show that c-terminal Tyr 530 is a de facto c-Src autophosphorylation site with slow time-resolution kinetics and a strong intermolecular component. On the contrary, activation-loop Tyr 419 undergoes faster kinetics and a cis-to-trans phosphorylation switch that controls c-terminal Tyr 530 autophosphorylation, enzyme specificity, and strikingly, c-Src non-catalytic function as a substrate. In line with this, we visualize by X-ray crystallography a snapshot of Tyr 530 intermolecular autophosphorylation. In an asymmetric arrangement of both catalytic domains, a c-terminal palindromic phospho-motif flanking Tyr 530 on the substrate molecule engages the G-loop of the active kinase adopting a position ready for entry into the catalytic cleft. Perturbation of the phospho-motif accounts for c-Src dysfunction as indicated by viral and colorectal cancer (CRC)-associated c-terminal deleted variants. We show that c-terminal residues 531 to 536 are required for c-Src Tyr 530 autophosphorylation, and such a detrimental effect is caused by the substrate molecule inhibiting allosterically the active kinase. Our work reveals a crosstalk between the activation and c-terminal segments that control the allosteric interplay between substrate- and enzyme-acting kinases during autophosphorylation.
- 17 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-21
Open AccessAn allosteric switch between the activation loop and a c-terminal palindromic phospho-motif controls c-Src function
Autophosphorylation controls the transition between discrete functional and conformational states in protein kinases, yet the structural and molecular determinants underlying this fundamental process remain unclear. Here we show that c-terminal Tyr 530 is a de facto c-Src autophosphorylation site with slow time-resolution kinetics and a strong intermolecular component. On the contrary, activation-loop Tyr 419 undergoes faster kinetics and a cis-to-trans phosphorylation switch that controls c-terminal Tyr 530 autophosphorylation, enzyme specificity, and strikingly, c-Src non-catalytic function as a substrate. In line with this, we visualize by X-ray crystallography a snapshot of Tyr 530 intermolecular autophosphorylation. In an asymmetric arrangement of both catalytic domains, a c-terminal palindromic phospho-motif flanking Tyr 530 on the substrate molecule engages the G-loop of the active kinase adopting a position ready for entry into the catalytic cleft. Perturbation of the phospho-motif accounts for c-Src dysfunction as indicated by viral and colorectal cancer (CRC)-associated c-terminal deleted variants. We show that c-terminal residues 531 to 536 are required for c-Src Tyr 530 autophosphorylation, and such a detrimental effect is caused by the substrate molecule inhibiting allosterically the active kinase. Our work reveals a crosstalk between the activation and c-terminal segments that control the allosteric interplay between substrate- and enzyme-acting kinases during autophosphorylation.
- Open Access
- 1 December 2019
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 141, 855-867
Structural and biochemical insights into an engineered high-redox potential laccase overproduced in Aspergillus
- 1 December 2019
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 141, 855-867
Open AccessStructural and biochemical insights into an engineered high-redox potential laccase overproduced in Aspergillus
- Open Access
- 15 November 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 4809
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
The costimulation of immune cells using first-generation anti-4-1BB monoclonal antibodies (mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development, however, is restricted by significant off-tumor toxicities associated with FcγR interactions. Here, we have designed an Fc-free tumor-targeted 4-1BB-agonistic trimerbody, 1D8N/CEGa1, consisting of three anti-4-1BB single-chain variable fragments and three anti-EGFR single-domain antibodies positioned in an extended hexagonal conformation around the collagen XVIII homotrimerization domain. The1D8N/CEGa1 trimerbody demonstrated high-avidity binding to 4-1BB and EGFR and a potent in vitro costimulatory capacity in the presence of EGFR. The trimerbody rapidly accumulates in EGFR-positive tumors and exhibits anti-tumor activity similar to IgG-based 4-1BB-agonistic mAbs. Importantly, treatment with 1D8N/CEGa1 does not induce systemic inflammatory cytokine production or hepatotoxicity associated with IgG-based 4-1BB agonists. These results implicate FcγR interactions in the 4-1BB-agonist-associated immune abnormalities, and promote the use of the non-canonical antibody presented in this work for safe and effective costimulatory strategies in cancer immunotherapy.
- 15 November 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 4809
Open AccessA tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
The costimulation of immune cells using first-generation anti-4-1BB monoclonal antibodies (mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development, however, is restricted by significant off-tumor toxicities associated with FcγR interactions. Here, we have designed an Fc-free tumor-targeted 4-1BB-agonistic trimerbody, 1D8N/CEGa1, consisting of three anti-4-1BB single-chain variable fragments and three anti-EGFR single-domain antibodies positioned in an extended hexagonal conformation around the collagen XVIII homotrimerization domain. The1D8N/CEGa1 trimerbody demonstrated high-avidity binding to 4-1BB and EGFR and a potent in vitro costimulatory capacity in the presence of EGFR. The trimerbody rapidly accumulates in EGFR-positive tumors and exhibits anti-tumor activity similar to IgG-based 4-1BB-agonistic mAbs. Importantly, treatment with 1D8N/CEGa1 does not induce systemic inflammatory cytokine production or hepatotoxicity associated with IgG-based 4-1BB agonists. These results implicate FcγR interactions in the 4-1BB-agonist-associated immune abnormalities, and promote the use of the non-canonical antibody presented in this work for safe and effective costimulatory strategies in cancer immunotherapy.
- Open Access
- 28 June 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-17
Molecular basis of Tousled-Like Kinase 2 activation
Tousled-like kinases (TLKs) are required for genome stability and normal development in numerous organisms and have been implicated in breast cancer and intellectual disability. In humans, the similar TLK1 and TLK2 interact with each other and TLK activity enhances ASF1 histone binding and is inhibited by the DNA damage response, although the molecular mechanisms of TLK regulation remain unclear. Here we describe the crystal structure of the TLK2 kinase domain. We show that the coiled-coil domains mediate dimerization and are essential for activation through ordered autophosphorylation that promotes higher order oligomers that locally increase TLK2 activity. We show that TLK2 mutations involved in intellectual disability impair kinase activity, and the docking of several small-molecule inhibitors of TLK activity suggest that the crystal structure will be useful for guiding the rationale design of new inhibition strategies. Together our results provide insights into the structure and molecular regulation of the TLKs.
- 28 June 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-17
Open AccessMolecular basis of Tousled-Like Kinase 2 activation
Tousled-like kinases (TLKs) are required for genome stability and normal development in numerous organisms and have been implicated in breast cancer and intellectual disability. In humans, the similar TLK1 and TLK2 interact with each other and TLK activity enhances ASF1 histone binding and is inhibited by the DNA damage response, although the molecular mechanisms of TLK regulation remain unclear. Here we describe the crystal structure of the TLK2 kinase domain. We show that the coiled-coil domains mediate dimerization and are essential for activation through ordered autophosphorylation that promotes higher order oligomers that locally increase TLK2 activity. We show that TLK2 mutations involved in intellectual disability impair kinase activity, and the docking of several small-molecule inhibitors of TLK activity suggest that the crystal structure will be useful for guiding the rationale design of new inhibition strategies. Together our results provide insights into the structure and molecular regulation of the TLKs.
- 20 August 2017
- Published by Wiley in FEBS Letters
- Vol. 591 (18) , 2826-2835
A mechanism for cancer‐associated inactivation of NQO1 due to P187S and its reactivation by the consensus mutation H80R
The cancer‐associated P187S polymorphism in the NAD(P)H:quinone oxidoreductase 1 (NQO1) abolishes enzyme activity by strongly reducing FAD binding affinity. A single mammalian consensus mutation (H80R) protects P187S from inactivation. To provide mechanistic insight into these effects, we report here a detailed structural and thermodynamic characterization of FAD binding to these NQO1 variants. Our results show that H80R causes a population shift in the conformational ensemble of apo‐P187S, remodelling the structure and dynamics of the FAD‐binding site and reducing the energetic penalization arising from the equilibrium between apo‐ and holo‐states. Our analyses illustrate how single amino acid changes can profoundly affect structural and mechanistic features of protein functional traits, with implications for our understanding of protein evolution and human disease.
- 20 August 2017
- Published by Wiley in FEBS Letters
- Vol. 591 (18) , 2826-2835
A mechanism for cancer‐associated inactivation of NQO1 due to P187S and its reactivation by the consensus mutation H80R
The cancer‐associated P187S polymorphism in the NAD(P)H:quinone oxidoreductase 1 (NQO1) abolishes enzyme activity by strongly reducing FAD binding affinity. A single mammalian consensus mutation (H80R) protects P187S from inactivation. To provide mechanistic insight into these effects, we report here a detailed structural and thermodynamic characterization of FAD binding to these NQO1 variants. Our results show that H80R causes a population shift in the conformational ensemble of apo‐P187S, remodelling the structure and dynamics of the FAD‐binding site and reducing the energetic penalization arising from the equilibrium between apo‐ and holo‐states. Our analyses illustrate how single amino acid changes can profoundly affect structural and mechanistic features of protein functional traits, with implications for our understanding of protein evolution and human disease.